{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:10:24Z","timestamp":1779426624623,"version":"3.53.1"},"reference-count":20,"publisher":"Cambridge University Press (CUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2025,10]]},"abstract":"Abstract<\/jats:title>\n \n Introduction:<\/jats:title>\n Neonates with ductal-dependent CHD rely on the patency of the ductus arteriosus to maintain circulation. Alprostadil is utilised to maintain ductal patency, although optimal dosing has not been determined. This study aims to describe alprostadil dosing in neonates with ductal-dependent CHD.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This is a single-centre retrospective study including neonatal patients with ductal-dependent CHD who received alprostadil from January 2015 to December 2015 (cohort 1) and January 2021 to December 2021 (cohort 2). The primary objective was to describe alprostadil dosing in the two study periods. Secondary objectives included clinical outcomes and adverse events associated with different alprostadil dosing strategies.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Sixty-five patients met eligibility for inclusion in this study: thirty-eight patients in cohort 1 and twenty-seven patient s in cohort 2. Baseline demographics were similar between cohorts. Initial alprostadil dosing in cohort 1 and cohort 2 was 0.006 mcg\/kg\/min and 0.025 mcg\/kg\/min (\n p<\/jats:italic>\n = < 0.001), respectively. Patients in cohort 2 were found to have a higher incidence of apneic events, apneic events requiring respiratory support, and the incidence of fever \u226538 \u00b0C.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In this single-centre study, we report that higher doses of alprostadil were associated with an increased risk of adverse events, which should be validated by prospective multicentre studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1017\/s1047951125109542","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:14:13Z","timestamp":1757574853000},"page":"2067-2070","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Dosing of intravenous alprostadil in neonates with ductal-dependent CHD"],"prefix":"10.1017","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-7625","authenticated-orcid":false,"given":"Alyssa Renee","family":"Miles","sequence":"first","affiliation":[{"name":"Johns Hopkins All Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Abel","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arabela","family":"Stock","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children\u2019s Hospital"},{"name":"Johns Hopkins All Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Smith","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children\u2019s Hospital"},{"name":"Johns Hopkins All Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kiskaddon","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children\u2019s Hospital"},{"name":"Johns Hopkins All Children\u2019s Hospital"},{"name":"Johns Hopkins University School of Medicine"},{"name":"Johns Hopkins All Children\u2019s"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"S1047951125109542_ref15","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.096305"},{"key":"S1047951125109542_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(86)80391-6"},{"key":"S1047951125109542_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a060506"},{"key":"S1047951125109542_ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.59.1.169"},{"key":"S1047951125109542_ref6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.64.5.893"},{"key":"S1047951125109542_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02276712"},{"key":"S1047951125109542_ref10","first-page":"81","article-title":"Prostaglandin E1 treatment in ductus dependent congenital cardiac malformation: a review of the treatment of 34 neonates","volume":"35","author":"Host","year":"1988","journal-title":"Dan Med Bull"},{"key":"S1047951125109542_ref3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.55.2.238"},{"key":"S1047951125109542_ref11","doi-asserted-by":"publisher","DOI":"10.1136\/adc.59.11.1020"},{"key":"S1047951125109542_ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938020-00006"},{"key":"S1047951125109542_ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.64.5.899"},{"key":"S1047951125109542_ref12","doi-asserted-by":"publisher","DOI":"10.1136\/adc.60.11.1025"},{"key":"S1047951125109542_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02424943"},{"key":"S1047951125109542_ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.53.4.728"},{"key":"S1047951125109542_ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309302"},{"key":"S1047951125109542_ref19","doi-asserted-by":"publisher","DOI":"10.1515\/JPM.2004.069"},{"key":"S1047951125109542_ref20","doi-asserted-by":"publisher","DOI":"10.1139\/y73-031"},{"key":"S1047951125109542_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2012.10.007"},{"key":"S1047951125109542_ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951113001522"},{"key":"S1047951125109542_ref5","first-page":"823","article-title":"Alprostadil (Prostin VR pediatric sterile solution, The Upjohn Company)","volume":"16","author":"Roehl","year":"1982","journal-title":"Drug Intel Clin Phar"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951125109542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:59:27Z","timestamp":1779425967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951125109542\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1047951125109542"],"URL":"https:\/\/doi.org\/10.1017\/s1047951125109542","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}